Achieve Life Sciences (ACHV) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Verastem (VSTM) over the past year, gaining 108.4% versus a loss of 8.2%. Over five years, ACHV leads with a -10.7% price change compared with -75.0% for VSTM. Achieve Life Sciences is the larger company by market cap ($741.3 million vs $734.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | VSTM |
|---|---|---|
| Share price | $7.19 | $8.11 |
| Market cap | $741.31M | $734.47M |
| 1-day change | -0.69% | -1.88% |
| YTD return | +44.67% | +7.06% |
| 1-year return | +108.41% | -8.17% |
| 5-year return | -10.68% | -75.05% |
| EPS (TTM) | $-1.69 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $10.82 |
| 52-week low | $2.62 | $3.43 |
| Distance from 52-week high | -16.78% | -25.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +96.80% | +80.89% |
| Average volume | 1.44M | 2.29M |
| Shares outstanding | 103.10M | 90.56M |
| Employees | 28 | 102 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed VSTM by 116.6 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
ACHV vs VSTM FAQ
Which is bigger, Achieve Life Sciences or Verastem?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $741.31M compared with $734.47M for Verastem (VSTM).
Which stock has performed better over the past year, ACHV or VSTM?
ACHV returned +108.41% over the past 12 months, compared with -8.17% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Verastem in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Achieve Life Sciences and Biotechnology: Pharmaceutical Preparations for Verastem.